Günay GÖKER, Ilgın KAYA, Derya AYDIN, Nezahat GÜRLER

Üriner sistemden izole edilen Escherıchia coli, Klebsiella ve enterokok cinsi bakterilerde fosfomisin duyarlılığının araştırılması

Escherichia coli, Klebsiella ve enterokok cinsi bakteriler üriner sistem infeksiyonlarının önde gelen etkenlerindendir. Bu çalışmada Ağustos 2006-Ocak 2007 tarihleri arasında idrar örneklerinden infeksiyon etkeni olarak izole edilen 100 E.coli, 100 Klebsiella ve 100 enterokok cinsi bakteri incelemeye alınmış ve fosfomisin trometamol ile nitrofurantoin, ampisilin, norfloksasin, ampisilin-sulbaktam, kotrimoksazole karşı duyarlılıkları karşılaştırılmıştır. Bir Klebsiella pneumoniae suşu dışında fosfomisin trometamol incelenen tüm bakterilere etkili bulunmuştur. İkinci etkili antimikrobik olarak nitrofurantoin saptanmıştır.

Anahtar Kelimeler:

Fosfomisin, Klebsiella, İlaç direnci, bakteriyel, İdrar yolu enfeksiyonları, Nitrofurantoin, Escherichia coli, Enterococcus, Trometamin, Mikrobiyal duyarlılık testleri

Investigation of Escherichia coli, Klebsiella and Enterococcus spp. susceptibilities to fosfomycine tromethamole in urinary tract infections

Escherichia coli, Klebsiella and Enterococcus spp. are frequently isolated as urinary tract patogens. In this study 100 E.coli, 100 Klebsiella and 100 Enterococcus spp. strains isolated from urine samples as pathogens between August 2006 and January 2007 were studied and susceptibilities to fosfomycin tromethamole, nitrofurantoin, ampicillin, norfloxacin, ampicillin-sulbactam and trimethoprim-sulphametoxazole were compared. Fosfomycin tromethamole was found to be effective to all bacteria except one Klebsiella pneumoniae isolate. Nitrofurantoin was found to be the second most effective antimicrobic.

Keywords:

Fosfomycin, Klebsiella, Drug Resistance, Bacterial, Urinary Tract Infections, Nitrofurantoin, Escherichia coli, Enterococcus, Tromethamine, Microbial Sensitivity Tests,

PDF

___

1. Afşar İ, Gönül B, fiener AG, Türker M: Escherichia coli’nin klinik izolatlarının fosfomisin trometamol ve diğer antibiyotiklere in-vitro duyarlılığı, ANKEM Derg 2005;19(2):77-9.
2. Allerberger F, Klare I: In vitro activity of fosfomycin against vancomycin-resistant enterococci, J Antimicrob Chemother 1999;43(2):211-7.
3. Arredondo Grarcia JL, Figueroa-Damian R, Rosas A et al: Comparision of short-term treatment regimen of ciprofloxacin versus long-term treatment regimens of trimethoprim/sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract infections: a randomized, multicentre, open-label, prospective study, J Antimicrob Chemother 2004;54(4):840-3.
4. Arslan H, Kurt Azap Ö, Ergönül Ö, Timurkaynak E, Urinary Tract Infection Study Group: Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey, J Antimicrob Chemother 2005;56(5):914-8.
5. Aykut Arca E, Karabiber N: Üriner sistem Escherichia coli izolatlarının fosfomisin trometamol ve çeflitli antibiyotiklere karşı duyarlılıklarının karşı- laştırılması, Mikrobiyol Bült 2007;41(1):115-9.
6. Barry AL, Fuchs PC: In vitro susceptibility testing procedures for fosfomycin tromethamine, Antimicrob Agents Chemother 1991;35(6):1235-8.
7. Clinical and Laboratory Standards Institute (Çeviri editörü D Gür): Antimikrobik duyarlılık testleri için uygulama standartları, M100-S16, Bilimsel Tıp Yayınevi, Ankara (2006).
8. Cueto M, Lopez L, Hernandez JR et al: In vitro activity of fosfomycin against extended-spectrumß- laktamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures, Antimicrob Agents Chemother 2006;50(1):368-70.
9. Çelik İ, CihangiroĞlu M, Çabalak M ve ark: Hastane kaynaklı koagülaz negatif stafilokoklarda fosfomisin duyarlılığı ile metisilin direnci ve slaym yapımı ilişkisi, ANKEM Derg 2005;19(3):139-43.
10. Elhanan G, Tabenkin H, Yahalom R, Raz R: Single dose fosfomycin trometamol versus 5-day cephalexin regimen for treatment of uncomplicated lower urinary tract infection in women, Antimicrob Agents Chemother 1994;38(11):2612-4.
11. Fuchs PC, Barry AL, Brown SD: Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcus faecalis from ten North American medical centres by three methods, J Antimicrob Chemother 1999;43(1):137-40.
12. Garcia-Rodriguez JA, Trujillano Martin I, Baqu-ero F et al: In vitro activity of fosfomycin trometamol against pathogens from urinary tract infections: a Spanish multicenter study, J Chemother 1997;9(6):394-402.
13. Kahan FM, Kahan JS, Cassidy PJ, Kropp H: The mechanism of action of fosfomycin (phosphonomycin), Ann N Y Acad Sci 1974;235:364-86.
14. Kalhmer G, Menday P: Cross-resistance and associated resistance in 2478 Escherichia coli isolates from the Pan-European ECO-SENS Project surveying the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections, J Antimicrob Chemother 2003;52(1):128-31.
15. Marchese A, Gualco L, Debbia EA, Schito GC, Schito AM: In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance, Int J Antimicrob Agents 2003;22(Suppl 2):53-9.
16. Norrby SR: Urinary tract infections, “Finch RG, Greenwood D, Norrby SR, Whitley RJ (eds): Antibiotic and Chemotherapy, 8th ed” kitabında s.764-71, Churchill Livingstone, Philadelphia (2003).
17. Pullukcu H, Tasbakan M, Sipahi OR et al: Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections, Int J Antimicrob Agents 2006;29(1):62-5.
18. Stein GE: Single-dose treatment of acute cystitis with fosfomycin tromethamine, Ann Pharmacother 1998;32(2): 215-9.